Adamas shares plunge 45% after drug to help MS patients walk disappoints

Adamas Pharmaceuticals Inc said on Tuesday its drug to treat walking impairment in patients with multiple sclerosis did not show the clinical benefit the drugmaker was hoping for in a late-stage trial, sending shares of the company down 45%.